267 related articles for article (PubMed ID: 35777449)
1. Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives.
Yu XD; Wang JW
Biochem Pharmacol; 2022 Aug; 202():115157. PubMed ID: 35777449
[TBL] [Abstract][Full Text] [Related]
2. Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease.
Zhu C; Huai Q; Zhang X; Dai H; Li X; Wang H
Int J Biol Sci; 2023; 19(1):311-330. PubMed ID: 36594091
[TBL] [Abstract][Full Text] [Related]
3. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover.
Simon J; Ouro A; Ala-Ibanibo L; Presa N; Delgado TC; Martínez-Chantar ML
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861664
[TBL] [Abstract][Full Text] [Related]
4. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
Wang K; Wei Y; Xu R; Li Y; Mao C
Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
[TBL] [Abstract][Full Text] [Related]
5. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
6. Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis.
Martínez L; Torres S; Baulies A; Alarcón-Vila C; Elena M; Fabriàs G; Casas J; Caballeria J; Fernandez-Checa JC; García-Ruiz C
Oncotarget; 2015 Dec; 6(39):41479-96. PubMed ID: 26539645
[TBL] [Abstract][Full Text] [Related]
7. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
[TBL] [Abstract][Full Text] [Related]
8. Sphingolipid metabolism in non-alcoholic fatty liver diseases.
Régnier M; Polizzi A; Guillou H; Loiseau N
Biochimie; 2019 Apr; 159():9-22. PubMed ID: 30071259
[TBL] [Abstract][Full Text] [Related]
9. The ketogenic diet prevents steatosis and insulin resistance by reducing lipogenesis, diacylglycerol accumulation and protein kinase C activity in male rat liver.
Jani S; Da Eira D; Stefanovic M; Ceddia RB
J Physiol; 2022 Sep; 600(18):4137-4151. PubMed ID: 35974660
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease.
Kurek K; Piotrowska DM; Wiesiołek-Kurek P; Łukaszuk B; Chabowski A; Górski J; Zendzian-Piotrowska M
Liver Int; 2014 Aug; 34(7):1074-83. PubMed ID: 24106929
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
[TBL] [Abstract][Full Text] [Related]
12. Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants.
Rives C; Fougerat A; Ellero-Simatos S; Loiseau N; Guillou H; Gamet-Payrastre L; Wahli W
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33371482
[TBL] [Abstract][Full Text] [Related]
13. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
[TBL] [Abstract][Full Text] [Related]
14. Too Much of a Good Thing? An Evolutionary Theory to Explain the Role of Ceramides in NAFLD.
Poss AM; Summers SA
Front Endocrinol (Lausanne); 2020; 11():505. PubMed ID: 32849291
[TBL] [Abstract][Full Text] [Related]
15. Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis.
Branković M; Jovanović I; Dukić M; Radonjić T; Oprić S; Klašnja S; Zdravković M
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563534
[TBL] [Abstract][Full Text] [Related]
16. Sphingolipids at the Crossroads of NAFLD and Senescence.
Nikolova-Karakashian M
Adv Cancer Res; 2018; 140():155-190. PubMed ID: 30060808
[TBL] [Abstract][Full Text] [Related]
17. Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets.
Tanase DM; Gosav EM; Petrov D; Jucan AE; Lacatusu CM; Floria M; Tarniceriu CC; Costea CF; Ciocoiu M; Rezus C
Diagnostics (Basel); 2021 Nov; 11(11):. PubMed ID: 34829402
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting Ceramide Synthesis Attenuates Hepatic Steatosis and Fibrosis in Rats With Non-alcoholic Fatty Liver Disease.
Jiang M; Li C; Liu Q; Wang A; Lei M
Front Endocrinol (Lausanne); 2019; 10():665. PubMed ID: 31616384
[TBL] [Abstract][Full Text] [Related]
19. Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis.
Kasumov T; Li L; Li M; Gulshan K; Kirwan JP; Liu X; Previs S; Willard B; Smith JD; McCullough A
PLoS One; 2015; 10(5):e0126910. PubMed ID: 25993337
[TBL] [Abstract][Full Text] [Related]
20. Roles of Ceramides in Non-Alcoholic Fatty Liver Disease.
Hajduch E; Lachkar F; Ferré P; Foufelle F
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33669443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
